Axis-Shield launches fourth AxSYM assay with Abbott

Axis-Shield, the international in-vitro diagnostics (IVD) company, today announces that it has completed the development and manufacturing of a new assay for HbA1c (used to monitor diabetic treatment compliance) to run on the widely-placed AxSYM^® immunoassay analyser from Abbott.

The new test has been launched in non-US markets only, and is currently awaiting assay clearance by the FDA for U.S. launch. The test employs novel Axis-Shield patented technology developed through pioneering research at its Dundee plant, which allows measurement of this important marker on an automated high throughput system. The assay is the fourth to have been launched under the AxSYM^® xtra programme, whereby Axis-Shield produces tests in its own livery to run on this popular system. Other kits available through this collaboration with Abbott comprise anti-CCP (early detection of rheumatoid arthritis), Active-B12 (for more effective diagnosis of vitamin B12 deficiency), and D-dimer, used in the detection of deep vein thrombosis and pulmonary embolism. Svein Lien, Axis-Shield CEO, commented: “We are pleased to have launched this key assay on the AxSYM^® platform. The project has been technically challenging and its successful conclusion is a tribute to the expertise of our development scientists. We are now able to offer the test in the laboratory on AxSYM^® as well as in the doctor’s office and other alternate sites via our new Afinion™ Point-of-Care Analyser and the long-established NycoCard™ system”